The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Malaria infects millions of people worldwide causing serious morbidity and mortality. However, individuals do not develop natural immunity to malaria even after years of exposure to the parasite. There have be a multitude of attempts to make a vaccine , with products going to clinical trials, but no vaccine is able to provide adequate protection for the long term. We recently showed that Plasmodium had evolved a mechanism to kill cells that protect in the long-term. This study will investigate t ....Malaria infects millions of people worldwide causing serious morbidity and mortality. However, individuals do not develop natural immunity to malaria even after years of exposure to the parasite. There have be a multitude of attempts to make a vaccine , with products going to clinical trials, but no vaccine is able to provide adequate protection for the long term. We recently showed that Plasmodium had evolved a mechanism to kill cells that protect in the long-term. This study will investigate the mechanism by which the parasite kill these cells, so that novel therapies can be designed.Read moreRead less
Development Of A Safe Live Genetically Attenuated Blood Stage Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$822,191.00
Summary
Malaria presents an enormous global health problem, and also has a significant impact on social and economic development in countries where the disease is endemic. Our project will produce a live genetically-modified vaccine against Plasmodium falciparum, the parasite that causes the form of malaria mostly deadly to humans. Our development plan will include the first ever clinical trials of a malaria vaccine of this kind and will look at vaccine safety and effectiveness.
Formulation Of A Pan-species, Multi-stage Vaccine For The Malaria Eradication Agenda
Funder
National Health and Medical Research Council
Funding Amount
$777,611.00
Summary
GNT 1093311 entitled 'Formulation of a pan-species, multi-stage vaccine for the malaria eradication agenda' seeks to undertake the preclinical development of a saccharide conjugate vaccine directed towards all major species and stages of malaria. The objectives are: (i) to undertake the synthesis of the vaccine construct; (ii) to compare immunogenicity, formulation and efficacy of various vaccine constructs with a view to down-selecting the optimal combination to take to human clinical trial.
The major objective of this research is to advance the development of highly effective malaria vaccines through i) defining mechanisms and targets of human immunity to malaria to establish a rational basis for vaccine design; ii) advancing the development of lead candidates and promising new candidates and combinations; iii) advancing vaccine platforms that induce potent protective immune responses; iv) develop and validate urgently-needed immunological assays for vaccine development and testing
This an integrated program of basic research on antigen discovery and immune mechanisms, and preclinical research on novel vaccine platforms, formulations or delivery systems for the rational design and clinical testing of a next generation vaccine against malaria. This interdisciplinary research fosters strong national and international links and offers the potential for significant economic benefit to Australia.
The growing momentum towards elimination of malaria and the need to control of drug-resistant parasites means that new drugs and vaccines are needed. In this Fellowship I will use the human malaria challenge system that I have developed to test whether new drugs and vaccines for malaria are working sufficiently well to justify their full development. In this system healthy volunteers are deliberately infected with malaria and then cured before they become unwell.
Assessment Of Transgenic Plants Expressing Malaria Antigens As A Means Of Inducing Protective Immunity
Funder
National Health and Medical Research Council
Funding Amount
$112,000.00
Summary
Malaria infection of humans is one of the most important and deadly infectious diseases in the world, killing more than two million people each year. Traditionally, drugs and insecticides have been used to treat the disease and control its spread. Unfortunately, both of these have become much less effective and there now exist untreatable cases of malaria. Alternative control measures are urgently needed and this project focusses on the development of such an alternative, a vaccine against malar ....Malaria infection of humans is one of the most important and deadly infectious diseases in the world, killing more than two million people each year. Traditionally, drugs and insecticides have been used to treat the disease and control its spread. Unfortunately, both of these have become much less effective and there now exist untreatable cases of malaria. Alternative control measures are urgently needed and this project focusses on the development of such an alternative, a vaccine against malaria using plants transgenic for genes encoding vaccine molecules. Growing these plants not only provides a potentially inexpensive vaccine production system but also offers a potential delivery system such that immunisation may be possible simply through consumption of an edible vaccine. This project intends to investigate the possibility of using transgenic plants expressing malaria antigens to induce protective immunity against malaria infection. The results of this project will provide vitally important information in malaria vaccine production and delivery.Read moreRead less
A Novel Approach To Identify The Specific Antibody Characteristics Important For Protection From Malaria In Pregnant Women
Funder
National Health and Medical Research Council
Funding Amount
$1,011,223.00
Summary
Antibody protects against malaria, but the specific characteristics of protective antibody are unknown. Pregnant women lack antibody to parasite protein called VAR2CSA, explaining their malaria susceptibility. Using samples from vaccine trials and clinical studies in pregnant women, and a ‘Systems Serology’ approach, we will determine which naturally-acquired or vaccine induced antibodies protect pregnant women from malaria, and how variation in VAR2CSA sequences affects this protection.
We will investigate malaria, a parasitic disease that kills over 600,000 people a year. We will explore how the parasite identifies, invades and remodels the host cells in which it lives, scavenging nutrients and hiding from the immune system. We will characterize the proteins involved in these critical events, as they are potential targets for drugs and vaccines. We will study how parasites cause disease and how the host responds to infection.
Surface Antigens Of Plasmodium Falciparum-infected Erythrocytes And Immunity To Malaria In Humans
Funder
National Health and Medical Research Council
Funding Amount
$599,180.00
Summary
Malaria is a leading cause of death globally, particularly among children. Malaria parasites infect red blood cells and multiply inside them, resulting in severe illness if left untreated. Effective treatments are limited and currently there is no vaccine. In human studies, we aim to identify the target antigens of immune responses and immune mechanisms that protect against malaria. With this knowledge, vaccines can be designed against malaria to prevent serious illness and death.